Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from boosted protease inhibitor regimen to Biktarvy in virologically suppressed adults with HIV-1 and archived resistance
ISRCTN44453201Phase 4Completed
- Sponsor
- University of Sussex
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Sussex. Primary endpoint: Pure virologic response at Week 24. Started Sep 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN44453201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44453201.